200 related articles for article (PubMed ID: 38265568)
1. Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?
van de Loo ME; Andour L; van Heesewijk AE; Oosterkamp HM; Liefers GJ; Straver ME
Breast Cancer Res Treat; 2024 May; 205(1):5-16. PubMed ID: 38265568
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
Madigan LI; Dinh P; Graham JD
Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
[TBL] [Abstract][Full Text] [Related]
3. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.
Spring LM; Gupta A; Reynolds KL; Gadd MA; Ellisen LW; Isakoff SJ; Moy B; Bardia A
JAMA Oncol; 2016 Nov; 2(11):1477-1486. PubMed ID: 27367583
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcome of neoadjuvant endocrine treatment than surgery-first in female HR-positive/HER2-negative breast cancer patients-A NCDB analysis (2010-2016).
Xu P; Luo W; Hu J; Ma X; Hao Q; Hui W; Zhou Z; Lin S; Wang M; Wu H; Dai Z; Kang H
Cancer Med; 2024 Jun; 13(11):e7244. PubMed ID: 38859692
[TBL] [Abstract][Full Text] [Related]
7. Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials.
Huang L; Xu AM
Expert Rev Anticancer Ther; 2017 Apr; 17(4):327-334. PubMed ID: 28271747
[TBL] [Abstract][Full Text] [Related]
8. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
van Olmen JP; Jacobs CF; Bartels SAL; Loo CE; Sanders J; Vrancken Peeters MTFD; Drukker CA; van Duijnhoven FH; Kok M
Breast; 2024 Jun; 75():103726. PubMed ID: 38599047
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Kim HJ; Noh WC; Lee ES; Jung YS; Kim LS; Han W; Nam SJ; Gong G-; Kim HJ; Ahn SH
Breast Cancer Res; 2020 May; 22(1):54. PubMed ID: 32460816
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
[TBL] [Abstract][Full Text] [Related]
11. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis.
Wang Y; He L; Song Y; Wu Q; Wang H; Zhang B; Ma X
BMC Womens Health; 2020 Jan; 20(1):17. PubMed ID: 32005117
[TBL] [Abstract][Full Text] [Related]
12. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
13. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
Straver ME; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Wesseling J; Russell NS; Oldenburg HS; Antonini N; Vrancken Peeters MT
Ann Surg Oncol; 2010 Sep; 17(9):2411-8. PubMed ID: 20373039
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
[TBL] [Abstract][Full Text] [Related]
15. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy for Breast Cancer, Is Practice Changing? A Population-Based Review of Current Surgical Trends.
Graham PJ; Brar MS; Foster T; McCall M; Bouchard-Fortier A; Temple W; Quan ML
Ann Surg Oncol; 2015 Oct; 22(10):3376-82. PubMed ID: 26202561
[TBL] [Abstract][Full Text] [Related]
17. Treatment of breast cancer in countries with limited resources.
Carlson RW; Anderson BO; Chopra R; Eniu AE; Jakesz R; Love RR; Masetti R; Schwartsmann G;
Breast J; 2003; 9 Suppl 2():S67-74. PubMed ID: 12713499
[TBL] [Abstract][Full Text] [Related]
18. [BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Semiglazov VF; Semiglazov VV; Petrenko OL; Komyakhov AV; Dashyan GA; Paltuev RM; Semiglazova TY; Manikhas AG; Bozhok AA; Lalak IA
Vopr Onkol; 2015; 61(3):381-6. PubMed ID: 26242149
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use.
Iwamoto M; Takei H; Ninomiya J; Asakawa H; Kurita T; Yanagihara K; Iida S; Sakatani T; Ohashi R
J Nippon Med Sch; 2021 Nov; 88(5):448-460. PubMed ID: 33692294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
